UHRF2 mRNA expression is low in malignant glioma but silencing inhibits the growth of U251 glioma cells in vitro

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5137-5142

  Wu, Ting Feng ^a   Zhang, Wei ^b   Su, Zuo Peng ^a   Chen, San Song ^a   Chen, Gui Lin ^a   Wei, Yong Xin ^a   Sun, Ting ^a   Xie, Xue Shun ^a   Li, Bin ^a   Zhou, You Xin ^a   Du, Zi Wei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Wujiang First Hospital   (China)

Author keywords

Malignant glioma; NIRF; Ubiquitin PHD RING finger family; UHRF2

Indexed keywords

EID: 84874003728     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5137     Document Type: Article

References (35)

1. Bronner C, Achour M, Arima Y, et al (2007). The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther, 115, 419-34.
2. Fournier A, Sasai N, Nakao M, et al (2011). The role of methyl-binding proteins in chromatin organization and epigenome maintenance. Brief Funct Genomics, 11, 251-64,
3. Gibney ER, Nolan CM (2010) Epigenetics and gene expression. Heredity (Edinb), 105, 4-13.
4. Gilbertson RJ, Rich JN (2007). Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer, 7, 733-36.
5. Glaab E, Baudot A, Krasnogor N, et al (2010). Extending pathways and processes using molecular interaction networks to analyse cancer genome data. BMC Bioinformatics, 11, 597.
6. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
7. He X, Duan C, Chen J, et al (2009). Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. FEBS Lett, 583, 3501-7.
8. Iwata A, Nagashima Y, Matsumoto L, et al (2009). Intranuclear degradation of polyglutamine aggregates by the ubiquitin-proteasome system. J Biol Chem, 284, 9796-803.
9. Jansen M, Yip S, Louis DN (2010). Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol, 9, 717-26.
10. Johnson LM, Bostick M, Zhang X, et al (2007). The SRA methyl-cytosine-binding domain links DNA and histone methylation. Curr Biol, 17, 379-84.
11. Just WW (2012). FOCUS ON... Ubiquitin-related tumor suppressors. FEBS Lett, 586, 1389.
12. Kiessling AA, Bletsa R, Desmarais B, et al (2009). Evidence that human blastomere cleavage is under unique cell cycle control. J Assist Reprod Genet, 26, 187-95.
13. Knuutila S, Aalto Y, Autio K, et al (1999). DNA copy number losses in human neoplasms. Am J Pathol, 155, 683-94.
14. Kocarnik JD, Hutter CM, Slattery ML, et al (2010) Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. Cancer Epidemiol Biomarkers Prev, 19, 3131-9.
15. Kotliarov Y, Steed ME, Christopher N, et al (2006). High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res, 66, 9428-36.
16. Lee J, Kotliarova S, Kotliarov Y, et al (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9, 391-403.
17. Li Y, Mori T, Hata H, et al (2004). NIRF induces G1 arrest and associates with Cdk2. Biochem Biophys Res Commun, 319, 464-8.
18. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.
19. Malumbres M, Barbacid M (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer, 9, 153-66.
20. Mori T, Ikeda DD, Fukushima T, et al (2011). NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle, 10, 3284-99.
21. Mori T, Ikeda DD, Yamaguchi Y, et al (2012). NIRF/UHRF2 occupies a central position in the cell cycle network and allows coupling with the epigenetic landscape. FEBS Lett, 586, 1570-83.
22. Mori T, Li Y, Hata H, et al (2002). NIRF, a novel RING finger protein, is involved in cell-cycle regulation. Biochem Biophys Res Commun, 296, 530-6.
23. Mori T, Li Y, Hata H, et al (2004). NIRF is a ubiquitin ligase that is capable of ubiquitinating PCNP, a PEST-containing nuclear protein. FEBS Lett, 557, 209-14.
24. Nakayama KI , Nakayama K (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer, 6, 369-81.
25. Network CGAR (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-8.
26. Oliver L, Olivier C, Marhuenda FB, et al (2009). Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol, 2, 263-84.
27. Parry L, Clarke AR (2011). The Roles of the Methyl-CpG Binding Proteins in Cancer. Genes Cancer, 2, 618-30.
28. Pichler G, Wolf P, Schmidt CS, et al (2011). Cooperative DNA and histone binding by Uhrf2 links the two major repressive epigenetic pathways. J Cell Biochem, 112, 2585-93.
29. Qian G, Jin F, Chang L, et al (2012). NIRF, a novel ubiquitin ligase, interacts with hepatitis B virus core protein and promotes its degradation. Biotechnol Lett, 34, 29-36.
30. Ren J, Wen L, Gao X, et al (2009). DOG 1.0: illustrator of protein domain structures. Cell Res, 19, 271-3.
31. Ulrich TA, de Juan Pardo EM, Kumar S (2009). The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res, 69, 4167-74.
32. Wang F, Zhang P, Ma Y, et al (2012). NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. Cancer Lett, 314, 223-31.
33. Wen PY, Kesari S (2008). Malignant gliomas in adults. N Engl J Med, 359, 492-507.
34. Wu J, Liu S, Liu G, et al (2012). Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene, 31, 333-41.
35. Zhang J, Gao Q, Li P, et al (2011) S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance. Cell Res, 21, 1723-39